Interpreting neutral findings in CA-AKI prevention trials: additional methodological considerations
European Journal of Clinical Pharmacology · 2026-07 · 82 (7)
DOI: 10.1007/s00228-026-04125-4 ↗Kurz gefasst
Leserbrief in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 23.06.2026. Verfasst von Zubaida Bibi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Ayub Medical College, Abbottabad, Pakistan. drzubaida241@gmail.com. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Ayub Medical College, Abbottabad, Pakistan. drzubaida241@gmail.com.
- KUST, Kohat, Pakistan.
Zitieren
APA
Bibi, Z., & Ali, K. (2026). Interpreting neutral findings in CA-AKI prevention trials: additional methodological considerations. European Journal of Clinical Pharmacology, 82(7). https://doi.org/10.1007/s00228-026-04125-4
Vancouver
Bibi Z, Ali K. Interpreting neutral findings in CA-AKI prevention trials: additional methodological considerations. European Journal of Clinical Pharmacology. 2026;82(7). doi:10.1007/s00228-026-04125-4
BibTeX
@article{Bibi2026,
author = {Bibi, Zubaida and Ali, Kausar},
title = {Interpreting neutral findings in CA-AKI prevention trials: additional methodological considerations},
journal = {European Journal of Clinical Pharmacology},
year = {2026},
volume = {82},
number = {7},
doi = {10.1007/s00228-026-04125-4}
}
EUVIMED